Hydroxychloroquine for coronavirus has ‘no effect’ in clinical trials: Dr. Badley
Mayo Clinic Covid-19 Research Task Force chair Dr. Andrew Badley on discontinuing the use of hydroxychloroquine to treat coronavirus and how the side effects outweigh any benefits.
Researchers in England say they have the first evidence that a drug can improve COVID-19 survival: A steroid called dexamethasone reduced deaths by up to one third in severely ill hospitalized patients.
Continue Reading Below
Results were announced Tuesday and researchers said they would publish them soon. The study is a large, strict test that randomly assigned 2,104 patients to get the drug and compared them with 4,321 patients getting only usual care.
WHAT IS THE COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS?
The drug was given either orally or through an IV. It reduced deaths by 35% in patients who needed treatment with breathing machines and by 20% in those only needing supplemental oxygen. It did not appear to help less ill patients.